Liminatus Pharma (LIMN) Stock: Nasdaq Delisting Warning Sparks Volatile Trading Session

Table of Contents Shares of LIMN jumped 31% following Nasdaq’s delisting notification, though pre-market sessions saw sharp reversals. Company falls short of Nasdaq’s $50M market cap and $15M public float thresholds. Liminatus has until May 27 to file an appeal, otherwise trading halts on May 29. Significant price fluctuations reflect investor uncertainty over Nasdaq compliance status. Filing an appeal will temporarily halt the delisting process pending panel review. Shares of Liminatus Pharma, Inc. (LIMN) experienced dramatic movement following notification from Nasdaq regarding potential delisting. The stock finished the trading day at $0.2460, marking a substantial 30.99% increase, only to retreat significantly to $0.1830 during pre-market hours. This early morning decline wiped out the majority of the previous day’s impressive rally. Liminatus Pharma, Inc. Class A Common Stock, LIMN The company has fallen short of Nasdaq’s mandatory $50 million minimum for market value of listed securities. Furthermore, the biotechnology firm also failed to satisfy the $15 million market value requirement for publicly held shares. Nasdaq originally extended a 180-day grace period for Liminatus to achieve compliance. Unless Liminatus submits an appeal to the Nasdaq Hearings Panel by the May 27, 2026 deadline, the stock will be delisted. A suspension of trading activities would commence on May 29, 2026, should the company fail to file its appeal. Management has indicated its intention to pursue a hearing to prevent any trading suspension. Nasdaq Listing Rule 5450(b)(2)(A) requires companies to maintain at least $50 million in market value for their listed securities. This regulation exists to guarantee adequate market capitalization for ongoing exchange listing. Liminatus was unable to achieve this benchmark before the May 18, 2026 compliance deadline. The publicly held shares standard outlined in Rule 5450(b)(2)(C) establishes a $15 million floor. This criterion ensures proper public float levels to maintain market stability and trading liquidity. Liminatus failed to satisfy this condition during the 180-day compliance window. Should the company’s appeal be granted, both the suspension and delisting procedures will be temporarily halted. This allows Liminatus an opportunity to submit compliance strategies to the Nasdaq Panel for consideration. The panel’s decision will ultimately dictate whether the stock maintains its listing status. Trading in LIMN stock has shown exceptional volatility since the delisting announcement. Market participants responded dramatically to both the significant price surge and subsequent pre-market decline. This trading behavior underscores the uncertainty around the company’s Nasdaq compliance efforts and future direction. The pharmaceutical company had already revealed these compliance challenges in a Form 8-K submission dated November 25, 2025. Liminatus has traded beneath the mandatory market value benchmarks since November 19, 2025. Nasdaq issued several warnings and established deadlines for the company to remedy these deficiencies. This delisting scenario demonstrates Nasdaq’s rigorous application of its listing criteria. Firms unable to satisfy MVLS and MVPHS standards encounter swift regulatory action. The success of Liminatus’ appeal will decide whether the stock maintains its position on the Nasdaq Global Market. Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.